Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.2% |
| 2 | Technology | 14.19% |
| 3 | Financials | 12.33% |
| 4 | Consumer Staples | 10.22% |
| 5 | Industrials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1451
M/I Homes
MHO
$3.87B
| $7.42M | 0.01% |
259,900
+68,000
| +35% | +$1.85M |
|
1452
SiriusPoint
SPNT
$2.74B
| $7.42M | 0.01% |
533,634
+284,034
| +114% | +$3.61M |
|
|
ARGO
1453
DELISTED
Argo Group International Holdings, Ltd.
ARGO
| $7.42M | 0.01% |
140,761
+120,015
| +578% | +$6.61M |
|
1454
Belden
BDC
$5.32B
| $7.4M | 0.01% |
98,100
-120,975
| -55% | -$8.65M |
|
|
ECOL
1455
DELISTED
US Ecology, Inc.
ECOL
| $7.38M | 0.01% |
146,200
-42,700
| -23% | -$2.11M |
|
|
GLBL
1456
DELISTED
TerraForm Global, Inc. Class A Common Stock
GLBL
| $7.38M | 0.01% |
1,462,000
+685,191
| +88% | +$3.32M |
|
|
KYNB
1457
Kyntra Bio
KYNB
$29M
| $7.34M | 0.01% |
9,092
-7,712
| -46% | -$5.37M |
|
|
PRMW
1458
DELISTED
Primo Water Corporation
PRMW
| $7.33M | 0.01% |
576,755
-213,300
| -27% | -$2.65M |
|
1459
Open Text
OTEX
$5.92B
| $7.32M | 0.01% |
231,800
-6,316
| -3% | -$208K |
|
1460
MBIA
MBI
$259M
| $7.31M | 0.01% |
774,879
+517,879
| +202% | +$4.4M |
|
1461
MiMedx Group
MDXG
$614M
| $7.28M | 0.01% |
+486,400
| New | +$6.49M |
|
1462
Monarch Casino & Resort
MCRI
$2.23B
| $7.25M | 0.01% |
239,500
+11,300
| +5% | +$341K |
|
1463
SouthState Bank Corp
SSB
$10.8B
| $7.23M | 0.01% |
84,383
-22,567
| -21% | -$1.95M |
|
1464
Timberland Bancorp
TSBK
$360M
| $7.23M | 0.01% |
286,200
+21,710
| +8% | +$494K |
|
|
EGIO
1465
DELISTED
Edgio, Inc. Common Stock
EGIO
| $7.23M | 0.01% |
62,525
+3,070
| +5% | +$357K |
|
|
GTT
1466
DELISTED
GTT Communications, Inc.
GTT
| $7.23M | 0.01% |
228,365
+61,894
| +37% | +$1.83M |
|
1467
Sonida Senior Living
SNDA
$1.92B
| $7.2M | 0.01% |
31,573
+3,033
| +11% | +$655K |
|
1468
Agnico Eagle Mines
AEM
$94B
| $7.19M | 0.01% |
159,336
+54,936
| +53% | +$2.58M |
|
|
BPFH
1469
DELISTED
Boston Private Financial Holdings, Inc.
BPFH
| $7.16M | 0.01% |
466,200
-189,700
| -29% | -$2.94M |
|
1470
Anika Therapeutics
ANIK
$291M
| $7.15M | 0.01% |
144,900
-108,200
| -43% | -$4.98M |
|
|
EXFO
1471
DELISTED
EXFO INC.
EXFO
| $7.15M | 0.01% |
1,520,600
-17,290
| -1% | -$84.2K |
|
1472
Rush Enterprises Class B
RUSHB
$9.27B
| $7.14M | 0.01% |
441,225
+53,100
| +14% | +$793K |
|
1473
Jack Henry & Associates
JKHY
$10.9B
| $7.13M | 0.01% |
68,600
-41,800
| -38% | -$4.17M |
|
1474
BBVA Argentina
BBAR
$3.15B
| $7.12M | 0.01% |
376,050
+198,174
| +111% | +$3.7M |
|
|
FBNK
1475
DELISTED
First Connecticut Bancorp, Inc
FBNK
| $7.11M | 0.01% |
277,000
+37,500
| +16% | +$956K |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.